Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report
Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated substantial therapeutic efficacy in the treatment of cancer. However, immune-related adverse events, including myasthenia gravis (MG), present significant clinical challenges. This study presents the case of a 75-year-old male pa...
Saved in:
| Main Authors: | Ying Huang, Futian Wu, Yihan Xiong, Kangling Huang, Xin Chang, Xiaofeng Chen, Xiali Chen, Qiwen Zhang, Liangyu Zou, Xuejun Fu, Huadong Zhang, Qianhui Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864251333518 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections
by: Yufei Deng, et al.
Published: (2025-07-01) -
Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study
by: Lei Jin, et al.
Published: (2024-12-01) -
Pembrolizumab-induced myasthenia gravis with respiratory involvement and favorable clinical outcome
by: Cristoss Gregory, et al.
Published: (2025-07-01) -
Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report
by: Nadia Khalil, et al.
Published: (2025-01-01) -
Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis
by: O. V. Finleyson
Published: (2025-04-01)